2024 medical insurance price of olaparib/olaparib targeted drug

Olaparib/Olaparib (Olaparib) is an inhibitor that targets PARP (polyADP-ribose polymerase) and can be used to treat certain types of ovarian cancer, breast cancer, fallopian tube cancer, primary peritoneal cancer, and metastatic castration-resistant prostate cancer. In China, with the development of targeted therapy and personalized medicine, the use of olaparib as a targeted drug has attracted increasing attention. Regarding its medical insurance situation, it has also been changing in recent years, reflecting the balance between the country's policy on the inclusion of new drugs and actual clinical needs.

Olaparib has been included in the reimbursement scope of my country’s medical insurance. Since 2020, Lynparza has been classified as a Category B drug in the medical insurance, and its limited payment conditions are mainly for patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Since then, its domestically approved indications have been gradually included in medical insurance, including a new indication in 2023 for the first-line maintenance treatment of homologous recombination repair deficiency (HRD)-positive advanced ovarian cancer in combination with bevacizumab. So far, all four domestically approved indications of Lynparza have been included in the medical insurance catalog, and the population covered by medical insurance has been further expanded.

In terms of price, the original olaparib drug, which has been launched in China and has entered Class B medical insurance, has two specifications:100mg 7 tablets and 8 tablets and 150mg 56 tablets, with a price of about more than 6,000 yuan per box. Due to price differences between drugs of different specifications and reimbursement ratios in different regions, there may be differences in the price after reimbursement. However, compared with before, the medical insurance price of Lynparza has been reduced, reflecting the role of medical insurance policies in easing the financial burden on patients. Therefore, it is recommended that patients consult their local medical insurance department or hospital before purchasing to obtain more accurate reimbursement information.